{"id":390568,"date":"2018-10-22T00:00:00","date_gmt":"2018-10-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0021-2018-biopharma-gastroesophageal-cancer-unmet-need-us-eu-2018\/"},"modified":"2026-04-29T05:25:29","modified_gmt":"2026-04-29T05:25:29","slug":"unneon0021-2018-biopharma-gastroesophageal-cancer-unmet-need-us-eu-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0021-2018-biopharma-gastroesophageal-cancer-unmet-need-us-eu-2018\/","title":{"rendered":"Gastroesophageal Cancer | Unmet Need | US\/EU | 2018"},"content":{"rendered":"<p>The genetic complexity and heterogeneity of gastric and GEJ adenocarcinoma poses a significant challenge for the development of treatment strategies for these cancers. Despite advancements in the treatment algorithm with the use of Keytruda (Merck &#038; Co.) for metastatic gastric and GEJ adenocarcinoma tumors expressing PD-L1 and Herceptin (Roche\/Genentech) for HER2-positive metastatic gastric or GEJ adenocarcinoma, therapeutic options for a large proportion of metastatic patients remain severely limited. Cyramza (Eli Lilly), with or without paclitaxel, is frequently prescribed for second- and subsequent-line treatment of metastatic gastric and GEJ adenocarcinoma. Cytotoxic monotherapies and doublet or triplet chemotherapy regimens remain a mainstay of treatment. The substantial unmet medical need for therapeutic management of metastatic gastric and GEJ adenocarcinoma with efficacious and well-tolerated novel therapies presents an attractive opportunity for drug developers.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for metastatic gastric and GEJ adenocarcinoma?<\/li>\n<li>What attributes are key influencers, which have limited impact, and which are hidden opportunities for drug developers?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for metastatic gastric and GEJ adenocarcinoma?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in metastatic gastric and GEJ adenocarcinoma?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, United Kingdom.<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 30 European medical oncologists fielded in June 2018.<\/p>\n<p><strong>Key companies:<\/strong> Roche\/Genentech, Eli Lilly, Merck &#038; Co.<\/p>\n<p><strong>Key drugs:<\/strong> Herceptin, Cyramza, Keytruda.<\/p>\n","protected":false},"template":"","class_list":["post-390568","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-esophageal-cancer","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390568\/revisions"}],"predecessor-version":[{"id":576704,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390568\/revisions\/576704"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}